Tarlatamab + Temozolomide for glioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Nov 2025: Trial started, NCT07243470
  2. 24 Nov 2025: Trial registered, NCT07243470

The trials

NCT07243470: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
70 planned
Started
4 Nov 2025
Primary completion
Oct 2029
Arms
Patients with IDH-mutant glioma, Patients with other glioma, Patients with other CNS tumors
Results
None posted
  1. 4 Nov 2025: Trial started
  2. 24 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.